文献速递心血管乳腺MRUS

系列心血管磁共振应变测量识别乳腺癌心脏毒性:与超声心动图比较

Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
PubMed 文献 · JACC Cardiovasc Imaging · 2020-11-25

本研究前瞻性纳入125例接受蒽环类/曲妥珠单抗治疗的HER2+早期乳腺癌女性,比较CMR与2DE应变、容积和LVEF对癌症治疗相关心功能障碍(CTRCD)的预后价值。CMR和2DE应变、LVEF及LVESVi变化均对后续CTRCD有预后意义;2DE-GLS相对基线临床风险因素提供的判别增值最高,2DE下GLS是最佳预后指标,CMR精确测量LVEF时FT应变可作为附加确认指标。

要点

  • 2DE-GLS相对降低15%使后续CTRCD风险增加133%,优于tagged-CMR GLS/GCS(47%/50%)和FT-GCS(87%)。
  • CMR和2DE的LVEF及LVESVi变化均与后续CTRCD相关。
  • 2DE下GLS是最佳预后应变指标,CMR精确测LVEF时FT应变可作附加确认。

核心结论

  • 在HER2+早期乳腺癌女性中,CMR和2DE的应变、LVEF及LVESVi变化对后续CTRCD有预后价值。
  • 当LVEF能由CMR精确测量时,FT应变可能作为附加确认性预后指标,但2DE下GLS是最佳预后指标。

研究设计与样本

  • 前瞻性招募125例接受序贯蒽环类/曲妥珠单抗治疗的HER2+早期乳腺癌女性,治疗前及治疗中完成5次系列CMR和6次2DE检查。
  • 测量CMR左室容积、tagged-CMR左室射血分数、特征追踪(FT) derived整体纵向应变(GLS)和整体周向应变(GCS),以及2DE左室容积、功能和GLS、GCS。
  • CTRCD采用心脏审查与评估委员会标准定义。

诊断标准与关键数值

  • CTRCD定义采用心脏审查与评估委员会标准。
  • 2DE-GLS相对降低15%使后续随访CTRCD的比值增加133%,tagged-CMR GLS/GCS分别增加47%/50%,FT-GCS增加87%。
  • CMR-LVEF和FT应变对后续CTRCD的预后阈值变化与这些测量的已知最小可检测差异相似,tagged-CMR应变的预后阈值低于最小可检测差异;2DE仅GLS的预后阈值大于最小可检测差异。
  • 2DE-LVEF或LVESVi联合应变相对临床风险因素使后续CTRCD的曲线下面积增加18%至22%,优于CMR LVEF或LVESVi联合应变的9%至14%。

临床应用与阅片要点

  • 2DE-GLS相对降低15%对后续CTRCD的预后判别增值在所有应变方法中最高。
  • 2DE下GLS是最佳预后应变指标;CMR精确测量LVEF时FT应变可能作为附加确认性预后指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study sought to compare the prognostic value of cardiovascular magnetic resonance (CMR) and 2-dimensional echocardiography (2DE) derived left ventricular (LV) strain, volumes, and ejection fraction for cancer therapy-related cardiac dysfunction (CTRCD) in women with early stage breast cancer.

BACKGROUND: There are limited comparative data on the association of CMR and 2DE derived strain, volumes, and LVEF with CTRCD.

METHODS: A total of 125 prospectively recruited women with HER2+ early stage breast cancer receiving sequential anthracycline/trastuzumab underwent 5 serial CMR and 6 of 2DE studies before and during treatment. CMR LV volumes, left ventricular ejection fraction tagged-CMR, and feature-tracking (FT) derived global systolic longitudinal (GLS) and global circumferential strain (GCS) and 2DE-based LV volumes, function, GLS, and GCS were measured. CTRCD was defined by the cardiac review and evaluation committee criteria.

RESULTS: Twenty-eight percent of patients developed CTRCD by CMR and 22% by 2DE. A 15% relative reduction in 2DE-GLS increased the CTRCD odds by 133% at subsequent follow-up, compared with 47%/50% by tagged-CMR GLS/GCS and 87% by FT-GCS. CMR and 2DE-LVEF and indexed left ventricular end-systolic volume (LVESVi) were also associated with subsequent CTRCD. The prognostic threshold change in CMR-left ventricular ejection fraction and FT strain for subsequent CTRCD was similar to the known minimum-detectable difference for these measures, whereas for tagged-CMR strain it was lower than the minimum-detectable difference; for 2DE, only the prognostic threshold for GLS was greater than the minimum-detectable difference. Of all strain methods, 2DE-GLS provided the highest increase in discriminatory value over baseline clinical risk factors for subsequent CTRCD. The combination of 2DE-left ventricular ejection fraction or LVESVi and strain provided greater increase in the area under the curve for subsequent CTRCD over clinical risk factors than CMR left ventricular ejection fraction or LVESVi and strain (18% to 22% vs. 9% to 14%).

CONCLUSIONS: In women with HER2+ early stage breast cancer, changes in CMR and 2DE strain, left ventricular ejection fraction, and LVESVi were prognostic for subsequent CTRCD. When LVEF can be measured precisely by CMR, FT strain may function as an additional confirmatory prognostic measure, but with 2DE, GLS is the optimal prognostic measure. (Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI [EMBRACE-MRI]; NCT02306538).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Houbois CP, Nolan M, Somerset E, et al. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography. JACC Cardiovasc Imaging. 2020. PMID: 33248962. doi:10.1016/j.jcmg.2020.09.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。